<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02049502</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00071015</org_study_id>
    <nct_id>NCT02049502</nct_id>
  </id_info>
  <brief_title>FMT in Ulcerative Colitis-Associated Pouchitis</brief_title>
  <official_title>The Use of Fecal Microbiota Transplantation in Patients With Ulcerative Colitis-associated Pouchitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia O. Shaffer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether Fecal Microbiota Transplant (FMT) is a safe and
      effective treatment for people who have Ulcerative Colitis and have had an ileal pouch
      anastomosis.

      Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) that may be caused by a
      person's immune system responding in an unusual way to bacteria normally found in the gut.
      Studies have shown that the gut bacteria in people with ulcerative colitis (UC) are different
      from the gut bacteria in people without ulcerative colitis (UC). Often, people with
      ulcerative colitis (UC) have fewer types of bacteria in their gut which can change the way
      that person's immune system works.

      This study is for people who have had a proctocolectomy with an ileal pouch anastomosis
      (IPAA) to treat ulcerative colitis (UC). More than 50% of people who have had an IPAA will
      develop a condition called pouchitis. Pouchitis is short or long-term inflammation of the
      ileal pouch that was created in order to store waste from your intestines. Patients with
      pouchitis are being asked to take part in this study.

      Currently, antibiotics, probiotics and prebiotics are used to treat pouchitis. However, it
      has been shown that probiotics are not very helpful once the patient stops taking them. In
      addition, antibiotics may cause unfavorable side effects. Fecal microbiota transplantation
      (FMT) is being studied as another form of treatment for patients with active pouchitis. Fecal
      microbiota transplantation (FMT) or &quot;stool transplant&quot; involves receiving a single fecal
      enema from someone who has volunteered to donate their stool.

      There are two purposes of this research study:

        1. To see whether or not fecal microbiota transplantation (FMT) is a useful treatment for
           patients with ulcerative colitis (UC) associated pouchitis

        2. To study the changes within the bacteria in the gut in patients with pouchitis (before
           and after study treatment) using stool, blood and urine samples
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">February 1, 2018</completion_date>
  <primary_completion_date type="Actual">February 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Who Experienced Improvement of Pouchitis Symptoms</measure>
    <time_frame>3 months</time_frame>
    <description>Improvement of clinical pouchitis symptoms based on the clinical component of the modified pouchitis disease activity index (mPDAI) without relapse. These components include: stool frequency (number of stools), rectal bleeding, fecal urgency or abdominal cramps, or fever (temperature &gt;37.8C).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Favorable Microbiota Profile</measure>
    <time_frame>3 months</time_frame>
    <description>16s ribosomal gene sequencing and metabolomic profile of the gut microbiota</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Ulcerative Colitis Associated Pouchitis</condition>
  <arm_group>
    <arm_group_label>fecal microbiota transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fecal microbiota transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>biologically active human fecal microbiota</intervention_name>
    <description>instillation of biologically active human fecal microbiota material via flexible sigmoidoscopy</description>
    <arm_group_label>fecal microbiota transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sigmoidoscopy</intervention_name>
    <arm_group_label>fecal microbiota transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female

          -  age 18 to 65 years

          -  ulcerative colitis-associated pouchitis

          -  patients of Emory Clinic and/or Emory University Hospital

        Exclusion Criteria:

          -  Age &lt;18 years or &gt;65 years of age

          -  Exposure to immunosuppressive therapy (defined as steroid, etanercept, or anti-tumor
             necrosis factor (TNF)agents) within 1 month prior to enrollment

          -  Concomitant Clostridium difficile infection

          -  Suspected Crohn's disease

          -  Documented active infection of any kind

          -  Patients on anti-coagulant therapy, with platelet count less than 50,000, significant
             anemia with hemoglobin less than 7 or those with other conditions that place them at
             increased risk of bleeding

          -  Absolute neutrophil count (ANC) less than 1000 or history of opportunistic infection

          -  Administration of investigational drug within one month prior to planned FMT

          -  Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginia O. Shaffer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory St. Joseph's Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 27, 2014</study_first_submitted>
  <study_first_submitted_qc>January 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2014</study_first_posted>
  <results_first_submitted>February 23, 2019</results_first_submitted>
  <results_first_submitted_qc>February 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 19, 2019</results_first_posted>
  <last_update_submitted>March 18, 2019</last_update_submitted>
  <last_update_submitted_qc>March 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Virginia O. Shaffer</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>ulcerative colitis</keyword>
  <keyword>fecal microbiota transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Pouchitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT02049502/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fecal Microbiota Transplant</title>
          <description>fecal microbiota transplant
biologically active human fecal microbiota: instillation of biologically active human fecal microbiota material via flexible sigmoidoscopy
sigmoidoscopy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fecal Microbiota Transplant</title>
          <description>fecal microbiota transplant
biologically active human fecal microbiota: instillation of biologically active human fecal microbiota material via flexible sigmoidoscopy
sigmoidoscopy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Experienced Improvement of Pouchitis Symptoms</title>
        <description>Improvement of clinical pouchitis symptoms based on the clinical component of the modified pouchitis disease activity index (mPDAI) without relapse. These components include: stool frequency (number of stools), rectal bleeding, fecal urgency or abdominal cramps, or fever (temperature &gt;37.8C).</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fecal Microbiota Transplant</title>
            <description>fecal microbiota transplant
biologically active human fecal microbiota: instillation of biologically active human fecal microbiota material via flexible sigmoidoscopy
sigmoidoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Experienced Improvement of Pouchitis Symptoms</title>
          <description>Improvement of clinical pouchitis symptoms based on the clinical component of the modified pouchitis disease activity index (mPDAI) without relapse. These components include: stool frequency (number of stools), rectal bleeding, fecal urgency or abdominal cramps, or fever (temperature &gt;37.8C).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Favorable Microbiota Profile</title>
        <description>16s ribosomal gene sequencing and metabolomic profile of the gut microbiota</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fecal Microbiota Transplant</title>
            <description>fecal microbiota transplant
biologically active human fecal microbiota: instillation of biologically active human fecal microbiota material via flexible sigmoidoscopy
sigmoidoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Favorable Microbiota Profile</title>
          <description>16s ribosomal gene sequencing and metabolomic profile of the gut microbiota</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fecal Microbiota Transplant</title>
          <description>fecal microbiota transplant
biologically active human fecal microbiota: instillation of biologically active human fecal microbiota material via flexible sigmoidoscopy
sigmoidoscopy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rectal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Increase in stool frequency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Shaffer</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-5033</phone>
      <email>virginia.o.shaffer@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

